This scientific commentary refers to ‘Clinical markers of disease progression in the prodromal to overt alpha-synucleinopathy continuum’ by Roascio et al. (https://doi.org/10.1093/brain/awag193).
In the original publication [...].
Carelli et al. argue that new insights into how NQO1 influences the response to idebenone warrant reevaluating the results of previous clinical trials, including those in Friedreich ataxia and Duchenne muscular dystrophy, using patient stratification by NQO1 genotype.
This Viewpoint examines how clinicians should approach amyloid-targeting therapies in patients with Alzheimer disease and suspected copathologies, emphasizing individualized decision-making, current evidence gaps, and the need for prospective studies.
[This corrects the article DOI: 10.3389/fpsyt.2026.1764492.].
<jats:p>None.</jats:p>
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
